Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 12 | 2019 | 160 | 3.280 |
Why?
|
Cystectomy | 11 | 2019 | 103 | 2.290 |
Why?
|
Prostatectomy | 11 | 2016 | 83 | 1.310 |
Why?
|
Prostatic Neoplasms | 8 | 2016 | 269 | 0.930 |
Why?
|
Internet | 6 | 2009 | 121 | 0.780 |
Why?
|
Nephrectomy | 4 | 2015 | 47 | 0.750 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2019 | 55 | 0.750 |
Why?
|
Laparoscopy | 7 | 2022 | 143 | 0.700 |
Why?
|
Cell-Penetrating Peptides | 1 | 2019 | 6 | 0.660 |
Why?
|
Cell Membrane Permeability | 1 | 2019 | 42 | 0.650 |
Why?
|
Cytosol | 1 | 2019 | 47 | 0.650 |
Why?
|
Green Fluorescent Proteins | 1 | 2019 | 100 | 0.650 |
Why?
|
Students, Medical | 4 | 2009 | 95 | 0.630 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 27 | 0.630 |
Why?
|
Risk Assessment | 7 | 2018 | 586 | 0.610 |
Why?
|
Vocational Guidance | 2 | 2008 | 3 | 0.610 |
Why?
|
Aged | 21 | 2019 | 5153 | 0.600 |
Why?
|
Peritoneal Cavity | 1 | 2017 | 13 | 0.600 |
Why?
|
Veins | 1 | 2017 | 19 | 0.590 |
Why?
|
Spectrum Analysis | 1 | 2017 | 29 | 0.590 |
Why?
|
Arteries | 1 | 2017 | 64 | 0.570 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2017 | 70 | 0.540 |
Why?
|
Adipose Tissue | 1 | 2017 | 179 | 0.530 |
Why?
|
Humans | 36 | 2021 | 26755 | 0.460 |
Why?
|
Carcinoma, Small Cell | 1 | 2013 | 14 | 0.450 |
Why?
|
Specialization | 3 | 2008 | 19 | 0.440 |
Why?
|
Neoadjuvant Therapy | 4 | 2014 | 67 | 0.440 |
Why?
|
Aged, 80 and over | 9 | 2018 | 1924 | 0.420 |
Why?
|
Ovarian Neoplasms | 1 | 2018 | 563 | 0.410 |
Why?
|
Male | 26 | 2021 | 12824 | 0.390 |
Why?
|
Robotic Surgical Procedures | 3 | 2017 | 43 | 0.380 |
Why?
|
United States | 10 | 2017 | 2031 | 0.370 |
Why?
|
Middle Aged | 16 | 2018 | 6791 | 0.370 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 100 | 0.370 |
Why?
|
Medicine | 2 | 2008 | 22 | 0.360 |
Why?
|
Software Design | 2 | 2008 | 7 | 0.360 |
Why?
|
Practice Patterns, Physicians' | 1 | 2012 | 160 | 0.350 |
Why?
|
Retrospective Studies | 11 | 2021 | 2436 | 0.350 |
Why?
|
Urethral Neoplasms | 1 | 2009 | 3 | 0.330 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 21 | 0.320 |
Why?
|
Ovariectomy | 2 | 2019 | 53 | 0.320 |
Why?
|
Postoperative Complications | 5 | 2015 | 605 | 0.310 |
Why?
|
Female | 14 | 2021 | 14408 | 0.300 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2007 | 4 | 0.300 |
Why?
|
Urination Disorders | 1 | 2007 | 9 | 0.300 |
Why?
|
Urethral Stricture | 1 | 2007 | 7 | 0.300 |
Why?
|
Urinary Diversion | 1 | 2007 | 26 | 0.300 |
Why?
|
Urologic Neoplasms | 2 | 2017 | 13 | 0.280 |
Why?
|
Anatomy, Artistic | 1 | 2006 | 1 | 0.280 |
Why?
|
Adult | 10 | 2021 | 7353 | 0.280 |
Why?
|
Medical Illustration | 1 | 2006 | 3 | 0.280 |
Why?
|
Histology | 1 | 2006 | 7 | 0.280 |
Why?
|
Computer-Assisted Instruction | 1 | 2006 | 27 | 0.270 |
Why?
|
Databases, Factual | 4 | 2017 | 251 | 0.260 |
Why?
|
Education, Medical | 1 | 2006 | 61 | 0.260 |
Why?
|
Prostatic Hyperplasia | 2 | 2015 | 8 | 0.260 |
Why?
|
Urethral Diseases | 2 | 2015 | 6 | 0.260 |
Why?
|
Penile Diseases | 2 | 2015 | 9 | 0.250 |
Why?
|
Penis | 2 | 2015 | 16 | 0.250 |
Why?
|
Urethra | 2 | 2015 | 33 | 0.250 |
Why?
|
Risk Factors | 8 | 2015 | 2012 | 0.230 |
Why?
|
Adenocarcinoma | 2 | 2016 | 284 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 309 | 0.210 |
Why?
|
Multivariate Analysis | 3 | 2017 | 297 | 0.190 |
Why?
|
Adrenocortical Carcinoma | 1 | 2021 | 5 | 0.190 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2021 | 6 | 0.190 |
Why?
|
Tomography, Optical Coherence | 1 | 2022 | 86 | 0.190 |
Why?
|
Swine | 2 | 2022 | 220 | 0.190 |
Why?
|
Neoplasm Invasiveness | 5 | 2014 | 180 | 0.180 |
Why?
|
Insurance, Health | 2 | 2017 | 51 | 0.180 |
Why?
|
Hep G2 Cells | 1 | 2019 | 28 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2014 | 108 | 0.170 |
Why?
|
Fluorescence | 1 | 2019 | 47 | 0.160 |
Why?
|
Biological Transport | 1 | 2019 | 107 | 0.160 |
Why?
|
Microscopy, Confocal | 1 | 2019 | 110 | 0.160 |
Why?
|
Prophylactic Surgical Procedures | 1 | 2018 | 7 | 0.160 |
Why?
|
Lysosomes | 1 | 2019 | 54 | 0.160 |
Why?
|
Endocytosis | 1 | 2019 | 81 | 0.160 |
Why?
|
Ovary | 1 | 2019 | 69 | 0.160 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 651 | 0.160 |
Why?
|
HeLa Cells | 1 | 2019 | 206 | 0.160 |
Why?
|
Prognosis | 6 | 2021 | 758 | 0.160 |
Why?
|
Gene Editing | 1 | 2018 | 18 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 189 | 0.150 |
Why?
|
CRISPR-Cas Systems | 1 | 2018 | 43 | 0.150 |
Why?
|
Urologists | 1 | 2017 | 5 | 0.150 |
Why?
|
Physicians, Primary Care | 1 | 2017 | 9 | 0.150 |
Why?
|
Intraoperative Period | 1 | 2017 | 21 | 0.150 |
Why?
|
Watchful Waiting | 2 | 2015 | 18 | 0.150 |
Why?
|
Insurance Coverage | 1 | 2017 | 33 | 0.150 |
Why?
|
Time Factors | 3 | 2017 | 1564 | 0.140 |
Why?
|
American Cancer Society | 1 | 2017 | 4 | 0.140 |
Why?
|
Logistic Models | 3 | 2016 | 397 | 0.140 |
Why?
|
Societies, Medical | 1 | 2017 | 89 | 0.140 |
Why?
|
Medicaid | 1 | 2017 | 54 | 0.140 |
Why?
|
Regression Analysis | 1 | 2017 | 209 | 0.140 |
Why?
|
Ureter | 1 | 2015 | 7 | 0.130 |
Why?
|
Neoplasm Staging | 5 | 2017 | 456 | 0.130 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2015 | 2 | 0.130 |
Why?
|
Carcinoma, Ductal | 1 | 2015 | 3 | 0.130 |
Why?
|
Registries | 2 | 2017 | 379 | 0.130 |
Why?
|
Rhabdomyolysis | 1 | 2015 | 6 | 0.130 |
Why?
|
Lymph Node Excision | 1 | 2015 | 94 | 0.130 |
Why?
|
Administration, Intravesical | 1 | 2015 | 16 | 0.130 |
Why?
|
BCG Vaccine | 1 | 2015 | 13 | 0.130 |
Why?
|
Prostate | 1 | 2015 | 51 | 0.130 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2015 | 12 | 0.130 |
Why?
|
Conversion to Open Surgery | 1 | 2015 | 2 | 0.120 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 52 | 0.120 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 33 | 0.120 |
Why?
|
Survival Rate | 4 | 2021 | 407 | 0.120 |
Why?
|
Population Surveillance | 1 | 2015 | 85 | 0.120 |
Why?
|
Robotics | 1 | 2015 | 42 | 0.120 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 144 | 0.120 |
Why?
|
Tennessee | 3 | 2008 | 25 | 0.120 |
Why?
|
Young Adult | 2 | 2018 | 2575 | 0.120 |
Why?
|
Follow-Up Studies | 3 | 2015 | 981 | 0.110 |
Why?
|
Immunotherapy | 1 | 2015 | 133 | 0.110 |
Why?
|
Perioperative Care | 1 | 2014 | 35 | 0.110 |
Why?
|
Carcinoma | 1 | 2014 | 71 | 0.110 |
Why?
|
Disease Progression | 1 | 2015 | 450 | 0.110 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 290 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2016 | 2262 | 0.100 |
Why?
|
Animals | 3 | 2022 | 9918 | 0.090 |
Why?
|
Hydronephrosis | 1 | 2010 | 11 | 0.090 |
Why?
|
Adolescent | 2 | 2021 | 2949 | 0.090 |
Why?
|
Feedback | 1 | 2009 | 32 | 0.080 |
Why?
|
Patient Readmission | 1 | 2010 | 103 | 0.080 |
Why?
|
Incidence | 3 | 2015 | 545 | 0.080 |
Why?
|
Urothelium | 1 | 2009 | 35 | 0.080 |
Why?
|
Pharmacy Administration | 1 | 2008 | 1 | 0.080 |
Why?
|
Medical Informatics Applications | 1 | 2008 | 7 | 0.080 |
Why?
|
Community Health Centers | 1 | 2008 | 13 | 0.080 |
Why?
|
Program Development | 1 | 2008 | 74 | 0.080 |
Why?
|
Schools, Medical | 1 | 2008 | 45 | 0.080 |
Why?
|
Urinary Catheterization | 1 | 2007 | 15 | 0.070 |
Why?
|
Anastomosis, Surgical | 1 | 2007 | 37 | 0.070 |
Why?
|
Career Choice | 1 | 2007 | 52 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2007 | 51 | 0.070 |
Why?
|
Prospective Studies | 3 | 2021 | 1217 | 0.070 |
Why?
|
Morbidity | 2 | 2015 | 57 | 0.060 |
Why?
|
Neoplasm Grading | 2 | 2015 | 104 | 0.060 |
Why?
|
Muscle, Smooth | 2 | 2014 | 40 | 0.060 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 119 | 0.050 |
Why?
|
Computers | 1 | 2022 | 29 | 0.050 |
Why?
|
Needles | 1 | 2022 | 26 | 0.050 |
Why?
|
Adrenalectomy | 1 | 2021 | 13 | 0.050 |
Why?
|
Genetic Code | 1 | 2018 | 2 | 0.040 |
Why?
|
Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 13 | 0.040 |
Why?
|
RNA, Guide | 1 | 2018 | 14 | 0.040 |
Why?
|
Lysine | 1 | 2018 | 69 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2018 | 107 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2021 | 845 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2017 | 18 | 0.040 |
Why?
|
Infant | 1 | 2021 | 960 | 0.040 |
Why?
|
Child, Preschool | 1 | 2021 | 1084 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2018 | 487 | 0.030 |
Why?
|
Margins of Excision | 1 | 2016 | 8 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 60 | 0.030 |
Why?
|
Rupture | 1 | 2015 | 11 | 0.030 |
Why?
|
Learning Curve | 1 | 2015 | 13 | 0.030 |
Why?
|
Operative Time | 1 | 2015 | 40 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2015 | 32 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2015 | 225 | 0.030 |
Why?
|
Radiotherapy | 1 | 2015 | 39 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2015 | 148 | 0.030 |
Why?
|
Child | 1 | 2021 | 2144 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 624 | 0.030 |
Why?
|
Risk | 1 | 2015 | 133 | 0.030 |
Why?
|
Biopsy | 1 | 2015 | 199 | 0.030 |
Why?
|
Forecasting | 1 | 2015 | 71 | 0.030 |
Why?
|
Odds Ratio | 1 | 2015 | 231 | 0.030 |
Why?
|
Oklahoma | 1 | 2017 | 968 | 0.030 |
Why?
|
Income | 1 | 2014 | 38 | 0.030 |
Why?
|
Length of Stay | 1 | 2015 | 218 | 0.030 |
Why?
|
Clinical Competence | 1 | 2015 | 204 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2014 | 90 | 0.030 |
Why?
|
Comorbidity | 1 | 2014 | 250 | 0.030 |
Why?
|
Cohort Studies | 1 | 2015 | 858 | 0.030 |
Why?
|
Age Factors | 1 | 2014 | 713 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 80 | 0.020 |
Why?
|
Boston | 1 | 2009 | 7 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 213 | 0.020 |
Why?
|
Consumer Behavior | 1 | 2009 | 14 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2009 | 21 | 0.020 |
Why?
|
Data Collection | 1 | 2009 | 101 | 0.020 |
Why?
|
Mice | 1 | 2018 | 4389 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2008 | 31 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2008 | 51 | 0.020 |
Why?
|
Software | 1 | 2009 | 121 | 0.020 |
Why?
|
Curriculum | 1 | 2009 | 257 | 0.020 |
Why?
|
Teaching | 1 | 2007 | 76 | 0.020 |
Why?
|